A Phase 1 Study of Anti-TGFβ Receptor Type-Ii Monoclonal Antibody LY3022859 in Patients With Advanced Solid Tumors
Cancer Chemotherapy and Pharmacology - Germany
doi 10.1007/s00280-017-3245-5
Full Text
Open PDFAbstract
Available in full text
Date
March 9, 2017
Authors
Publisher
Springer Science and Business Media LLC